Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-Pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-Pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

FDA Scraps Biannual Biologics Inspections for Risk-Based Approach

  • Post author:Sam
  • Post published:May 6, 2019
  • Post category:Drug GMP Report

The FDA is scrapping requirements that biologics be inspected at least every two years, moving instead to a risk-based schedule. Source: Drug GMP Report

Continue ReadingFDA Scraps Biannual Biologics Inspections for Risk-Based Approach

FDA Issues List of Class 1 Accessories

  • Post author:Sam
  • Post published:May 3, 2019
  • Post category:The GMP Letter

The FDA has finalized a list of accessories that can be classified as Class 1 devices. The listing was required under the FDA Reauthorization Act of 2017. Source: The GMP…

Continue ReadingFDA Issues List of Class 1 Accessories

FDA Clarifies Labeling Identifier Rules for Convenience Kits

  • Post author:Sam
  • Post published:May 3, 2019
  • Post category:The GMP Letter

The FDA considers first aid and other “convenience” kits a single device for regulatory purposes, the agency said in final guidance. Source: The GMP Letter

Continue ReadingFDA Clarifies Labeling Identifier Rules for Convenience Kits

Combination Products Get Extra Year for Postmarket Safety Compliance

  • Post author:Sam
  • Post published:May 3, 2019
  • Post category:The GMP Letter

The FDA gave sponsors of combination drug/device products another year to get their IT affairs in order before complying with new postmarket safety reporting requirements. Source: The GMP Letter

Continue ReadingCombination Products Get Extra Year for Postmarket Safety Compliance

FDA Issues Final Guidance on Bench Performance Testing

  • Post author:Sam
  • Post published:May 3, 2019
  • Post category:The GMP Letter

The FDA issued final guidance recommending what information devicemakers should include in test report summaries, test protocols and complete rest reports for non-clinical bench performance testing for their premarket submissions.…

Continue ReadingFDA Issues Final Guidance on Bench Performance Testing

CDRH Flags Ongoing Concerns Over Contaminated Duodenoscopes

  • Post author:Sam
  • Post published:May 3, 2019
  • Post category:The GMP Letter

CDRH Director Jeff Shuren said the center is considering regulatory actions because of ongoing concerns over contaminated duodenoscopes. Source: The GMP Letter

Continue ReadingCDRH Flags Ongoing Concerns Over Contaminated Duodenoscopes

483 Roundup: FDA Flags Three Firms for Quality, Other Issues

  • Post author:Sam
  • Post published:May 3, 2019
  • Post category:The GMP Letter

The FDA cited three devicemakers for nonconforming products, documentation failures, inadequate CAPAs and numerous other problems found during agency inspections. Source: The GMP Letter

Continue Reading483 Roundup: FDA Flags Three Firms for Quality, Other Issues

FDA Addresses Safety Concerns for Surgical Staplers and Staples

  • Post author:Sam
  • Post published:May 3, 2019
  • Post category:The GMP Letter

The FDA issued a draft guidance and proposed order designed to ensure the safe and effective use of surgical staplers and staples for internal use. Source: The GMP Letter

Continue ReadingFDA Addresses Safety Concerns for Surgical Staplers and Staples

European Commission Releases Details on Eudamed, Nomenclature System

  • Post author:Sam
  • Post published:May 3, 2019
  • Post category:The GMP Letter

The European Commission released long-awaited guidance on Eudamed (the European Database on Medical Devices) and the device nomenclature system that will be used for the EU’s new medical device and…

Continue ReadingEuropean Commission Releases Details on Eudamed, Nomenclature System

Minnesota Drugmaker Cited for Cleaning Deficiencies

  • Post author:Sam
  • Post published:April 29, 2019
  • Post category:Drug Industry Daily

The FDA hit Minnesota generic drug manufacturer Upsher Smith Laboratories with a Form 483 over cleaning and batch production violations at its Plymouth facility. Source: Drug Industry Daily

Continue ReadingMinnesota Drugmaker Cited for Cleaning Deficiencies
  • Go to the previous page
  • 1
  • …
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • …
  • 610
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.